Nitroglycerin enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via nitric oxide pathway

Li Huang, Ni Qiu, Che Zhang, Hong Yan Wei, Ya Lin Li, Hong Hao Zhou, Zhousheng Xiao

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aim: To investigate the effect of nitroglycerin (NTG) on cell proliferation and osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells (HBMSC) and its mechanisms. Methods: Primary HBMSC were cultured in osteogenic differentiation medium consisting of phenol red-free α-minimum essential media plus 10% fetal bovine serum (dextran-coated charcoal stripped) supplemented with 10 nmol/L dexamethasone, 50 mg/L ascorbic acid, and 10 mmol/L β-glycerophosphate for inducing osteoblastic differentiation. The cells were treated with NTG (0.1-10 μmol/L) alone or concurrent incubation with different nitric oxide synthase (NOS) inhibitors. Nitric oxide (NO) production was measured by using a commercial NO kit. Cell proliferation was measured by 5-bromodeoxyuridine (BrdU) incorporation. The osteoblastic differentiation of HBMSC culture was evaluated by measuring cellular alkaline phosphatase (ALP) activity and calcium deposition, as well as osteoblastic markers by real-time RT-PCR. Results: The treatment of HBMSC with NTG (0.1-10 μmol/L) led to a dose-dependent increase of NO production in the conditional medium. The release of NO by NTG resulted in increased cell proliferation and osteoblastic differentiation of HBMSC, as evidenced by the increment of the BrdU incorporation, the induction of ALP activity in the early stage, and the calcium deposition in the latter stage. The increment of NO production was also correlated with the upregulation of osteoblastic markers in HBMSC cultures. However, the stimulatory effect of NTG (10 μmol/L) could not be abolished by either N G -nitro-L-arginine methyl ester, an antagonist of endothelial NOS, or 1400W, a selective blocker of inducible NOS activity. Conclusion: NTG stimulates cell proliferation and osteoblastic differentiation of HBMSC through a direct release of NO, which is independent on intracellular NOS activity.

Original languageEnglish (US)
Pages (from-to)580-586
Number of pages7
JournalActa Pharmacologica Sinica
Volume29
Issue number5
DOIs
StatePublished - May 1 2008

Fingerprint

Nitroglycerin
Mesenchymal Stromal Cells
Nitric Oxide
Bone Marrow
Cell Proliferation
Bromodeoxyuridine
Nitric Oxide Synthase
Alkaline Phosphatase
Cell Culture Techniques
Phenolsulfonphthalein
Calcium
Glycerophosphates
Nitric Oxide Synthase Type III
Charcoal
NG-Nitroarginine Methyl Ester
Nitric Oxide Synthase Type II
Dextrans
Dexamethasone
Ascorbic Acid
Real-Time Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Nitroglycerin enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via nitric oxide pathway. / Huang, Li; Qiu, Ni; Zhang, Che; Wei, Hong Yan; Li, Ya Lin; Zhou, Hong Hao; Xiao, Zhousheng.

In: Acta Pharmacologica Sinica, Vol. 29, No. 5, 01.05.2008, p. 580-586.

Research output: Contribution to journalArticle

Huang, Li ; Qiu, Ni ; Zhang, Che ; Wei, Hong Yan ; Li, Ya Lin ; Zhou, Hong Hao ; Xiao, Zhousheng. / Nitroglycerin enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via nitric oxide pathway. In: Acta Pharmacologica Sinica. 2008 ; Vol. 29, No. 5. pp. 580-586.
@article{67c9580335b8477dbc5012a91de7274f,
title = "Nitroglycerin enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via nitric oxide pathway",
abstract = "Aim: To investigate the effect of nitroglycerin (NTG) on cell proliferation and osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells (HBMSC) and its mechanisms. Methods: Primary HBMSC were cultured in osteogenic differentiation medium consisting of phenol red-free α-minimum essential media plus 10{\%} fetal bovine serum (dextran-coated charcoal stripped) supplemented with 10 nmol/L dexamethasone, 50 mg/L ascorbic acid, and 10 mmol/L β-glycerophosphate for inducing osteoblastic differentiation. The cells were treated with NTG (0.1-10 μmol/L) alone or concurrent incubation with different nitric oxide synthase (NOS) inhibitors. Nitric oxide (NO) production was measured by using a commercial NO kit. Cell proliferation was measured by 5-bromodeoxyuridine (BrdU) incorporation. The osteoblastic differentiation of HBMSC culture was evaluated by measuring cellular alkaline phosphatase (ALP) activity and calcium deposition, as well as osteoblastic markers by real-time RT-PCR. Results: The treatment of HBMSC with NTG (0.1-10 μmol/L) led to a dose-dependent increase of NO production in the conditional medium. The release of NO by NTG resulted in increased cell proliferation and osteoblastic differentiation of HBMSC, as evidenced by the increment of the BrdU incorporation, the induction of ALP activity in the early stage, and the calcium deposition in the latter stage. The increment of NO production was also correlated with the upregulation of osteoblastic markers in HBMSC cultures. However, the stimulatory effect of NTG (10 μmol/L) could not be abolished by either N G -nitro-L-arginine methyl ester, an antagonist of endothelial NOS, or 1400W, a selective blocker of inducible NOS activity. Conclusion: NTG stimulates cell proliferation and osteoblastic differentiation of HBMSC through a direct release of NO, which is independent on intracellular NOS activity.",
author = "Li Huang and Ni Qiu and Che Zhang and Wei, {Hong Yan} and Li, {Ya Lin} and Zhou, {Hong Hao} and Zhousheng Xiao",
year = "2008",
month = "5",
day = "1",
doi = "10.1111/j.1745-7254.2008.00778.x",
language = "English (US)",
volume = "29",
pages = "580--586",
journal = "Acta Pharmacologica Sinica",
issn = "1671-4083",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Nitroglycerin enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via nitric oxide pathway

AU - Huang, Li

AU - Qiu, Ni

AU - Zhang, Che

AU - Wei, Hong Yan

AU - Li, Ya Lin

AU - Zhou, Hong Hao

AU - Xiao, Zhousheng

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Aim: To investigate the effect of nitroglycerin (NTG) on cell proliferation and osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells (HBMSC) and its mechanisms. Methods: Primary HBMSC were cultured in osteogenic differentiation medium consisting of phenol red-free α-minimum essential media plus 10% fetal bovine serum (dextran-coated charcoal stripped) supplemented with 10 nmol/L dexamethasone, 50 mg/L ascorbic acid, and 10 mmol/L β-glycerophosphate for inducing osteoblastic differentiation. The cells were treated with NTG (0.1-10 μmol/L) alone or concurrent incubation with different nitric oxide synthase (NOS) inhibitors. Nitric oxide (NO) production was measured by using a commercial NO kit. Cell proliferation was measured by 5-bromodeoxyuridine (BrdU) incorporation. The osteoblastic differentiation of HBMSC culture was evaluated by measuring cellular alkaline phosphatase (ALP) activity and calcium deposition, as well as osteoblastic markers by real-time RT-PCR. Results: The treatment of HBMSC with NTG (0.1-10 μmol/L) led to a dose-dependent increase of NO production in the conditional medium. The release of NO by NTG resulted in increased cell proliferation and osteoblastic differentiation of HBMSC, as evidenced by the increment of the BrdU incorporation, the induction of ALP activity in the early stage, and the calcium deposition in the latter stage. The increment of NO production was also correlated with the upregulation of osteoblastic markers in HBMSC cultures. However, the stimulatory effect of NTG (10 μmol/L) could not be abolished by either N G -nitro-L-arginine methyl ester, an antagonist of endothelial NOS, or 1400W, a selective blocker of inducible NOS activity. Conclusion: NTG stimulates cell proliferation and osteoblastic differentiation of HBMSC through a direct release of NO, which is independent on intracellular NOS activity.

AB - Aim: To investigate the effect of nitroglycerin (NTG) on cell proliferation and osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells (HBMSC) and its mechanisms. Methods: Primary HBMSC were cultured in osteogenic differentiation medium consisting of phenol red-free α-minimum essential media plus 10% fetal bovine serum (dextran-coated charcoal stripped) supplemented with 10 nmol/L dexamethasone, 50 mg/L ascorbic acid, and 10 mmol/L β-glycerophosphate for inducing osteoblastic differentiation. The cells were treated with NTG (0.1-10 μmol/L) alone or concurrent incubation with different nitric oxide synthase (NOS) inhibitors. Nitric oxide (NO) production was measured by using a commercial NO kit. Cell proliferation was measured by 5-bromodeoxyuridine (BrdU) incorporation. The osteoblastic differentiation of HBMSC culture was evaluated by measuring cellular alkaline phosphatase (ALP) activity and calcium deposition, as well as osteoblastic markers by real-time RT-PCR. Results: The treatment of HBMSC with NTG (0.1-10 μmol/L) led to a dose-dependent increase of NO production in the conditional medium. The release of NO by NTG resulted in increased cell proliferation and osteoblastic differentiation of HBMSC, as evidenced by the increment of the BrdU incorporation, the induction of ALP activity in the early stage, and the calcium deposition in the latter stage. The increment of NO production was also correlated with the upregulation of osteoblastic markers in HBMSC cultures. However, the stimulatory effect of NTG (10 μmol/L) could not be abolished by either N G -nitro-L-arginine methyl ester, an antagonist of endothelial NOS, or 1400W, a selective blocker of inducible NOS activity. Conclusion: NTG stimulates cell proliferation and osteoblastic differentiation of HBMSC through a direct release of NO, which is independent on intracellular NOS activity.

UR - http://www.scopus.com/inward/record.url?scp=42649121955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42649121955&partnerID=8YFLogxK

U2 - 10.1111/j.1745-7254.2008.00778.x

DO - 10.1111/j.1745-7254.2008.00778.x

M3 - Article

VL - 29

SP - 580

EP - 586

JO - Acta Pharmacologica Sinica

JF - Acta Pharmacologica Sinica

SN - 1671-4083

IS - 5

ER -